BR0210317A - Complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções medianas por microorganismos patogênicos intracelulares nos mamìferos - Google Patents

Complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções medianas por microorganismos patogênicos intracelulares nos mamìferos

Info

Publication number
BR0210317A
BR0210317A BR0210317-6A BR0210317A BR0210317A BR 0210317 A BR0210317 A BR 0210317A BR 0210317 A BR0210317 A BR 0210317A BR 0210317 A BR0210317 A BR 0210317A
Authority
BR
Brazil
Prior art keywords
leishmaniasis
mammals
prevention
treatment
therapeutic vaccine
Prior art date
Application number
BR0210317-6A
Other languages
English (en)
Other versions
BRPI0210317B8 (pt
BRPI0210317C1 (pt
BRPI0210317B1 (pt
Inventor
Gerard Papierok
Serge Vicens
Jean-Loup Lemesre
Original Assignee
Bio Veto Tests
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Veto Tests filed Critical Bio Veto Tests
Publication of BR0210317A publication Critical patent/BR0210317A/pt
Publication of BRPI0210317B1 publication Critical patent/BRPI0210317B1/pt
Publication of BRPI0210317B8 publication Critical patent/BRPI0210317B8/pt
Publication of BRPI0210317C1 publication Critical patent/BRPI0210317C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMPLEXO DE VACINA TERAPêUTICA DESTINADO à PREVENçãO OU AO TRATAMENTO DE LEISHMANIOSES E INFECçõES MEDIADAS POR MICROORGANISMOS PATOGêNICOS INTRACELULARES NOS MAMìFEROS". Complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos e em particular no homem, nos caninos, nos felinos e nos eq³ídeos, caracterizado pelo fato de que ele é composto por moléculas de excreção secreção provenientes de promastigotos de Leishmania sp. produzidos em um meio sem germes e sem soro definido.
BRPI0210317A 2001-06-11 2002-05-30 complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos BRPI0210317C1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107606A FR2825633B1 (fr) 2001-06-11 2001-06-11 Complexe vaccinal therapeutique destine a la prevention et au traitement des leishmanioses et des infections a microorganismes pathogenes intracellulaires chez le mammifere
PCT/FR2002/001823 WO2002100430A1 (fr) 2001-06-11 2002-05-30 Complexe vaccinal destine a la prevention et au traitement des leishmanioses

Publications (4)

Publication Number Publication Date
BR0210317A true BR0210317A (pt) 2004-08-10
BRPI0210317B1 BRPI0210317B1 (pt) 2018-09-11
BRPI0210317B8 BRPI0210317B8 (pt) 2018-10-09
BRPI0210317C1 BRPI0210317C1 (pt) 2021-05-25

Family

ID=8864170

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0210317A BRPI0210317C1 (pt) 2001-06-11 2002-05-30 complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos

Country Status (10)

Country Link
US (1) US20060073170A1 (pt)
EP (1) EP1395282B1 (pt)
AT (1) ATE321568T1 (pt)
BR (1) BRPI0210317C1 (pt)
CY (1) CY1105309T1 (pt)
DE (1) DE60210276T2 (pt)
ES (1) ES2260440T3 (pt)
FR (1) FR2825633B1 (pt)
PT (1) PT1395282E (pt)
WO (1) WO2002100430A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968749B2 (en) * 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
EP2853269B1 (en) 2008-05-19 2019-05-01 Advaxis, Inc. Dual delivery system for heterologous antigens comprising a recombinant Listeria strain attenuated by mutation of dal/dat and deletion of ActA comprising a nucleic acid molecule encoding an listeriolysin O - prostate specific anigen fusion protein
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
EP2566506B1 (fr) * 2010-05-07 2016-07-06 Virbac Composition vaccinale destinee a la prevention ou au traitement des leishmanioses
CN103282048B (zh) * 2010-10-01 2017-05-17 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
KR20140134695A (ko) 2012-03-12 2014-11-24 어드박시스, 인크. 리스테리아 백신 치료 후 억제 세포 기능 저해

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206252A (en) * 1977-04-04 1980-06-03 Gordon Roy G Deposition method for coating glass and the like
US5599387A (en) * 1993-02-16 1997-02-04 Ppg Industries, Inc. Compounds and compositions for coating glass with silicon oxide
FR2705358B1 (fr) * 1993-05-13 1995-08-04 Orstom Procédé de culture in vitro de différents stades de parasites tissulaires, stades parasitaires obtenus et applications biologiques.
AU5820199A (en) * 1998-09-17 2000-04-03 Libbey-Owens-Ford Co. Heat strengthened coated glass article and method for making same
US6342925B1 (en) * 1999-01-15 2002-01-29 Sharp Laboratories Of America, Inc. Automatic audio and video parameter adjustment
CN101035277A (zh) * 2000-03-13 2007-09-12 索尼公司 产生压缩的代码转换提示元数据的方法和设备
KR100765925B1 (ko) * 2000-09-27 2007-10-11 톰슨 라이센싱 멀티미디어 디바이스를 위해 오디오 및 비디오 출력상태를 최적화하기 위한 구조
US6967588B2 (en) * 2002-03-25 2005-11-22 Sony Corporation System and method for controlling a home entertainment system

Also Published As

Publication number Publication date
WO2002100430B1 (fr) 2003-02-13
US20060073170A1 (en) 2006-04-06
BRPI0210317B8 (pt) 2018-10-09
CY1105309T1 (el) 2010-03-03
FR2825633A1 (fr) 2002-12-13
EP1395282B1 (fr) 2006-03-29
ATE321568T1 (de) 2006-04-15
PT1395282E (pt) 2006-07-31
BRPI0210317C1 (pt) 2021-05-25
EP1395282A1 (fr) 2004-03-10
DE60210276T2 (de) 2006-11-30
FR2825633B1 (fr) 2005-12-16
BRPI0210317B1 (pt) 2018-09-11
WO2002100430A1 (fr) 2002-12-19
ES2260440T3 (es) 2006-11-01
DE60210276D1 (de) 2006-05-18

Similar Documents

Publication Publication Date Title
BR9909668A (pt) Uso de compostos de organofósforo para o tratamento terapêutico e profilático de infecções
EA200400481A1 (ru) Применение флибансерина для лечения половых расстройств
MA26992A1 (fr) Derives de phenethanolamine pour le traitement des maladies respiratoires
DZ1877A1 (fr) Forme posologiques d'azithromycine pour le traitement d'infection microbiennes.
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
PT1326635E (pt) Composicao farmaceutica para imunizacao contra a sida
BR9609413A (pt) Formulações de dieta e farmacêuticas para a profilaxia e o tratamento de distúrbios gastrintestinais
MA27929A1 (fr) Utilisation de calcitonine pour le traitement de l'osteoarthrite
BR0111892A (pt) Bis-arilsulfonas
BRPI0210317B8 (pt) complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos
BR0211830A (pt) Dose única de azitromicina
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
MY139368A (en) Novel cyclohexyl sulphones
MXPA02012857A (es) Uso de una formulacion elaborada de o que contiene al menos un suero de leche dismilado.
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
BR0210632A (pt) Tratamento de doença parasìtica
ES2093257T3 (es) Utilizacion de torasemida para la preparacion de medicamentos destinados al tratamiento de edemas cerebrales.
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
ATE308895T1 (de) Behandlung von infektionen in tieren
BR0007491A (pt) Uso de 3-isoxazolidinonas e ácidos hidroxilâmicospara o tratamento de infecções
BR0309684A (pt) O tratamento de dor com ifendropil
AUPR412901A0 (en) Agents for the prevention and treatment of sexually transmitted disease s - II
BR0210875A (pt) Antìgenos de streptococcus do grupo b e fragmentos de dna correspondentes
BR0211533A (pt) Tratamento de dor crÈnica com 3-heterociclil- e 3-cicloalquil-3-ariloxipropanaminas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/09/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/09/2018, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2488 DE 11/09/2018, QUANTO AO NOME DO TITULAR.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/05/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2725 DE 28/03/2023 POR TER SIDO INDEVIDA, UMA VEZ QUE O PRAZO DE VALIDADE DA PATENTE TERMINOU EM 30/05/2022.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 30/05/2022